I. Introduction: The Cannabinoid Receptors and Their Response to Disease
The endocannabinoid system is uniquely poised to respond locally to disease. Endocannabinoids are synthesized "on demand" from membrane phospholipids in response to increases in intracellular calcium (as occurs with neuronal activation or cell stress) and immediately released to act in paracrine fashion on nearby G i/o -protein coupled receptors CB 1 R 1 and CB 2 R. Endocannabi- Neuropathic pain CB 1 R and CB 2 R up-regulated in peripheral and central sensory pathways in animal models of neuropathic pain (Siegling et al., 2001; Lim et al., 2003; Zhang et al., 2003; Walczak et al., 2005; Mitrirattanakul et al., 2006) .
Inhibition of neurotransmitter release decreases hyperexcitability of sensory pathways (CB 1 R); inhibition of inflammation (CB 2 R) (for review, see Costigan et al., 2009) .
CB 1 R up-regulation enhances analgesic response to exogenous cannabinoids in animal model of neuropathic pain (Lim et al., 2003) .
Neuroinflammation and brain injury CB 2 R up-regulated in microglia/ macrophage-like cells of patients with MS or ALS (Yiangou et al., 2006) and in microglia of EAE mouse model of MS (Maresz et al., 2005) .
CB 2 R expressed on T cells reduces inflammation in MS (Maresz et al., 2007) .
T-cell CB 2 R is already highly activated by endocannabinoids in MS; increasing receptor number is thus important for increasing efficacy of CB 2 R agonist (Maresz et al., 2007) .
CB 1 R up-regulated in rat brain after mild concussive head injury and NMDAR blockade (Hansen et al., 2001 ).
Neuroprotection by decreasing glutamate release/excitotoxicity, among other possible mechanisms (for review, see Mechoulam et al., 2002) . Cancer
Increased CB 1 R and CB 2 R expression in multiple human cancers (for review, see Sarfaraz et al., 2008) .
Cannabinoid receptor activation leads to apoptosis via cell cycle regulation and ER stress (for review, see Sarfaraz et al., 2008) .
Up-regulation of receptors may be crucial for antitumor effects of cannabinoids. For example, a nonselective agonist inhibits growth of prostate cancer cells with high expression of CB 1 R and CB 2 R (Sarfaraz et al., 2005) , whereas ⌬ 9 -THC stimulates growth in breast cancer cells with low expression (McKallip et al., 2005) . Increasing receptor expression where it is lost could be a novel therapeutic option (Wang et al., 2008) . Down-regulated CB 1 R in human colorectal tumors (Wang et al., 2008) .
Loss of CB 1 R leads to enhanced colorectal tumor proliferation in mouse model of colorectal cancer (Wang et al., 2008) . Gastrointestinal CB 1 R up-regulated in mouse model of diarrhea (Izzo et al., 2001) ; CB 1 R and CB 2 R up-regulated in multiple models of colitis (Massa et al., 2004; Kimball et al., 2006) . CB 1 R expressed on enteric neurons decreases intestinal motility, secretion, and visceral pain and promotes wound healing. CB 2 R expressed on gut immune cells decreases inflammation (for review, see Izzo and Camilleri, 2008) .
Up-regulation of CB 1 R probably accounts for increased efficacy and potency of agonists in slowing intestinal transit in mouse model of diarrhea (Izzo et al., 2001 ).
Liver
Hepatic CB 1 R and CB 2 R upregulated in cirrhosis in humans and rodent activated hepatic stellate cells (aHSCs) (Julien et al., 2005; Teixeira-Clerc et al., 2006; Jeong et al., 2008) .
Fibrogenic stimuli up-regulate hepatic CB 1 R, which stimulates lipogenesis in hepatocytes (Osei-Hyiaman et al., 2005) and promotes fibrogenesis through aHSCs and myofibroblasts (Teixeira-Clerc et al., 2006) . CB 2 R activation leads to apoptosis of profibrogenic aHSCs and myofibroblasts (Julien et al., 2005) .
Antagonism of CB 1 R and agonism of CB 2 R reduces proliferation of fibrogenic cells (Julien et al., 2005; Teixeira-Clerc et al., 2006) .
Hepatic CB 1 R also up-regulated in mice fed high-fat (Osei-Hyiaman et al., 2005; Jourdan et al., 2010; Quarta et al., 2010) and alcohol diets (Jeong et al., 2008) .
Antagonism of CB 1 R decreases hepatic fatty acid synthesis in mice fed highfat diet (Osei-Hyiaman et al., 2005) . CB 1 R antagonism also prevents highfat diet-induced increases in hepatic CB 1 R expression (Jourdan et al., 2010) .
Metabolic
Adipose CB 1 R up-regulated in Zucker rat model of obesity (Bensaid et al., 2003) and mice fed high-fat diet (Jourdan et al., 2010) .
CB 1 R stimulates lipogenesis and inhibits fatty acid oxidation in adipose cells and may increase insulin release from the pancreas (Matias et al., 2006 ; for review, see Kunos et al., 2008) .
CB 1 R up-regulation in adipocytes may account for increased efficacy of CB 1 R antagonist in reducing weight in obese compared with lean Zucker rats (Vickers et al., 2003) .
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noids are then rapidly cleared by cellular uptake and enzymatic degradation. Cannabinoid receptors work through a variety of signaling mechanisms to exert physiological and pathophysiological effects in different tissues. In neurons, where CB 1 R expression is highest, stimulation of presynaptic CB 1 R inhibits neurotransmitter release by stimulating potassium channels and inhibiting calcium channels (for review, see Howlett et al., 2002) . In the liver, where CB 1 R is normally expressed at low levels, stimulation of CB 1 R leads to enhanced expression of acetyl-CoA carboxylase-1 and fatty acid synthase and thus increases lipogenesis (Osei-Hyiaman et al., 2005) . CB 2 R expression is highest in immune cells, where it seems to have several immunosuppressive effects, including inhibition of proinflammatory cytokine production (Maresz et al., 2007) . Cannabinoid receptor signaling is discussed in detail in several recent reviews (Cabral and Griffin-Thomas, 2009; Turu and Hunyady, 2010) . In addition to increasing levels of endocannabinoids, the system often responds to stress by altering the expression of CB 1 R and/or CB 2 R. In some diseases, such as neuropathic pain and multiple sclerosis, increases in cannabinoid receptor expression are thought to reduce symptoms and/or inhibit progression of disease and thus serve a protective role (for review, see Pertwee, 2009 ). In other diseases, alterations in receptor expression are maladaptive, examples being CB 1 R up-regulation in liver fibrosis and down-regulation in colorectal cancer (Teixeira-Clerc et al., 2006; Wang et al., 2008) . In both cases, regulation of cannabinoid receptor expression is of interest from a therapeutics perspective. Regional upregulation of CB 1 R correlates with enhanced potency and efficacy of agonists at sites of disease in several animal models, including intestinal inflammation and hypertension (Izzo et al., 2001; Bá tkai et al., 2004) ; a more causal relationship was suggested in neuropathic pain, where inhibition of CB 1 R up-regulation reduced the analgesic effects of cannabinoids (Lim et al., 2003) . Regional up-regulation of CB 1 R is similarly thought to enhance efficacy of systemic antagonists in models of obesity (for review, see Vickers et al., 2003; Kunos et al., 2008) . Such up-regulation should therefore increase the benefit-to-side-effect ratio of systemic agonists (for review, see Pertwee, 2009 ) and antagonists. In addition, identifying the lack of cannabinoid receptor up-regulation could be important. For example, prostate cancer cells that highly express cannabinoid receptors respond favorably to agonists (Sarfaraz et al., 2005) , whereas breast cancer cells that express low levels of cannabinoid receptors show increased proliferation in response to Skeletal muscle CB 1 R up-regulated in mice fed high-fat diet (Pagotto et al., 2006) . CB 1 R up-regulation in skeletal muscle may contribute to insulin resistance in obesity (for review, see Kunos et al., 2008) .
CB 1 R antagonism prevents high-fat dietinduced increases in adipose CB 1 R expression (Jourdan et al., 2010) .
Cardiovascular CB 1 R up-regulated in myocardium and aorta in rat model of hypertension (Batkai et al., 2004) .
CB 1 R lowers blood pressure by decreasing cardiac contractility and vascular resistance, but this effect is only seen in hypertensive, not normotensive animals (Batkai et al., 2004) .
CB 1 R up-regulation in the heart and vasculature may account for increased potency and efficacy of agonists in hypertensive animals (Batkai et al., 2004) .
CB 2 R up-regulated in immune cells in atherosclerotic plaques in humans and mouse model (Steffens et al., 2005) .
CB 2 R decreases plaque progression, possibly by reducing infiltration of immune cells and cytokine release (Steffens et al., 2005) . Psychiatric CB 1 R up-regulated in prefrontal cortex of depressed suicide victims (Hungund et al., 2004) and patients with schizophrenia (Dean et al., 2001 ).
CB 1 R has both excitatory and inhibitory effects on synaptic transmission in the prefrontal cortex (Lafourcade et al., 2007; Chiu et al., 2010) ; the effect of its up-regulation in these diseases is not known.
Targeting the endocannabinoid system in these diseases will require better understanding of its role.
MS, multiple sclerosis; ALS, amyotrophic lateral sclerosis; EAE, experimental autoimmune encephalitis; NMDAR, N-methyl-D-aspartate receptor; ER, endoplasmic reticulum; ⌬ 9 -THC, tetrahydrocannabinol; aHSC, activated hepatic stellate cell. Di Marzo, 2008; Izzo and Camilleri, 2008) and are briefly summarized in Table 1 to emphasize the global nature of these alterations and their therapeutic implications.
II. Mechanisms of Cannabinoid Receptor Regulation
Despite the growing list of diseases that show cannabinoid receptor expression changes, relatively little is known about the mechanisms underlying these changes. In Table 2 , we summarize all current findings of which we are aware. These studies of mechanism span a number of diseases and vary in the level of detail, from investigating changes in cannabinoid receptor protein levels to promoter occupancy, but several themes are apparent across the disease models examined so far. For one, up-regulation is induced by factors that are released locally in response to disease, in accordance with the region-specific nature of these expression changes.
For example, spinal cord CB 1 R protein increases were found to be mediated in part by the Trk/MAPK pathway in a rat model of neuropathic pain, suggesting a mechanism by which neurotrophic factors released locally by nerve injury ) could modulate CB 1 R expression (Lim et al., 2003) . Spinal cord CB 1 R increases in neuropathic pain were also found to be mediated by glucocorticoids (Wang et al., 2007) . Although corticosteroids are increased systemically in the same model (Wang et al., 2004) , localized CB 1 R up-regulation is probably made possible by local increases in spinal glucocorticoid receptors (GR) (Wang et al., 2004) . Localized mechanisms of CB 1 R regulation were also observed in liver and immune cells. Retinoic acid, which is synthesized and stored by hepatic stellate cells, was found to increase CB 1 R transcription in hepatocytes through retinoic acid receptor-␥ (Mukhopadhyay et al., 2010) . Cytokines, which are released locally in inflammation to regulate neighboring immune cells, have been impli- Liver steatosis RAR-␥ binds the Ϫ500 to ϩ50 region of the CB 1 R promoter and increases its expression (Mukhopadhyay et al., 2010) .
Primary cultured mouse hepatocytes
Retinoic acid released from hepatic stellate cells induces CB 1 R expression in hepatocytes, which in turn induces lipogenesis (Jeong et al., 2008) . Inflammation Cannabinoids induce CB 1 R mRNA expression in T cells by an IL-4-and CB 2 R-dependent mechanism (Borner et al., 2007) .
Jurkat T cells CB 1 R is expressed at very low levels in resting T cells; when induced, it seems to have anti-inflammatory effects (MolinaHolgado et al., 2003; Nakajima et al., 2006) . These studies together suggest a feedback mechanism in T cells whereby cannabinoids induce expression of antiinflammatory IL-4 via CB 2 R, and IL-4 in turn increases CB 1 R transcription (Borner et al., 2008) . IL-4 directly increases CB 1 R mRNA expression in T cells via STAT6 binding to a STAT6 element at nt Ϫ2769 upstream from human exon1 TSS (Borner et al., 2008) .
Primary human T cells and Jurkat T cells
IFN␥ and GM-CSF synergize to increase CB 2 R mRNA expression in microglia (Maresz et al., 2005) .
Primary cultured mouse microglial cells
Increases in proinflammatory IFN␥ and GM-CSF could mediate the increased microglial expression of CB 2 R seen in EAE model of MS (Maresz et al., 2005) . Neuropathic Pain CB 1 R protein up-regulation in the spinal cord is mediated by Trk and MAPK (Lim et al., 2003) and GR (Wang et al., 2007) .
Rat chronic constriction injury model of neuropathic pain
Neurotrophic factors and corticosteroids released with nerve injury may mediate CB 1 R up-regulation via the Trk/MAPK pathway and GR, respectively (Lim et al., 2003; Wang et al., 2007) . Cancer Increased DNA methylation of CB 1 R promoter leads to decreased expression of CB 1 R (Wang et al., 2008) .
Human colorectal cancer cells Loss of CB 1 R expression leads to enhanced tumor proliferation in a mouse model of colorectal cancer (Wang et al., 2008) ; first evidence of a role for epigenetics in CB 1 R regulation. Feeding behaviors and energy homeostasis CNS-specific knockout of SF-1 leads to loss of CB 1 R expression in the ventromedial hypothalamus. SF-1 directly increases CB 1 R expression via SF-1 element at nt Ϫ101 within the mouse promoter (Kim et al., 2008) .
CNS-specific SF-1 knockout mouse and various cell lines CNS-specific SF-1 knockouts do not show the appetite-stimulating effects of CB 1 R agonists. SF-1 regulation of CB 1 R expression in the VMH is thus required for cannabinoid effects on food intake (Kim et al., 2008 cated in up-regulation of both CB 1 R and CB 2 R in immune cells (Maresz et al., 2005; Börner et al., 2008) . Second, the regulatory factors identified so far are common to many physiological and pathophysiological processes and could thus be starting points for investigation of cannabinoid receptor regulation in other disease models. For example, retinoic acid has been implicated in cell survival, differentiation, axonal outgrowth, and immune regulation (for review, see Maden, 2007; Montrone et al., 2009; Noy, 2010) , whereas neurotrophic factors have been implicated in neuronal survival and synaptic plasticity (for review, see Huang and Reichardt, 2001) . A role for epigenetics, a widespread mechanism by which diseases cause long-lasting changes in gene expression by DNA and histone modifications, is also emerging. Downregulation of CB 1 R in human colorectal cancer cells has been attributed to methylation of the CB 1 R promoter and leads to enhanced tumor proliferation in animal models (Wang et al., 2008) .
Finally, autoregulation is an emerging and intriguing mechanism of cannabinoid receptor regulation. Endocannabinoids and exogenous cannabinoids have been implicated in CB 1 R up-regulation in hepatocytes and T cells, respectively (Börner et al., 2007; Mukhopadhyay et al., 2010) , and long-term CB 1 R antagonism has been found to counter increases in hepatic and adipose CB 1 R expression in response to high-fat diet (Jourdan et al., 2010) . In addition, administration of a mixed CB 1 R/ CB 2 R agonist increases expression of the CB 2 A isoform (see section IV.B) in mouse cerebellum (Liu et al., 2009) . Because endocannabinoids are often increased along with cannabinoid receptors in disease (Mitrirattanakul et al., 2006; Jeong et al., 2008) , such autoinduction is probably common to many diseases. Understanding this autoregulation is also important from a therapeutics standpoint. Cannabinoid receptor antagonists could produce their effects through down-regulation of cannabinoid receptors in addition to blockade of cannabinoid receptor signaling pathways, whereas agonists could increase receptor expression in addition to stimulation of signaling pathways and thus amplify response to treatment.
III. Therapeutic Implications
The mechanisms of cannabinoid receptor regulation not only shed light on the pathophysiology of a disease but are also of interest from a therapeutics perspective. The challenge remains to selectively target the endocannabinoid system while sparing other areas, particularly mood and cognitive centers of the brain. As mentioned in section I, regional increases in cannabinoid receptor expression are thought to selectively enhance the effects of agonists at sites of disease, thus increasing their benefit-to-side-effect ratio (for review, see Pertwee, 2009 ). In diseases for which cannabinoid receptors are protective, knowledge of the mechanisms of this receptor up-regulation could be used to design therapies to regionally enhance receptor expression and thus further optimize benefitto-side effect ratio or eliminate the need for systemic agonists altogether. In neuropathic pain, for example, enhanced analgesic effect of cannabinoids has been linked to increases in spinal cord CB 1 R expression (Lim et al., 2003) . As mentioned in section I, this up-regulation is mediated in part by Trk/MAPK pathways and glucocorticoid receptors (Lim et al., 2003; Wang et al., 2007) . Increasing spinal cord CB 1 R expression by local administration of Trk agonists or glucocorticoids could further increase the efficacy and potency of exogenous cannabinoids and thus allow for lower, nonpsychotropic doses. Moreover, increases in endocannabinoid production in neuropathic pain (Mitrirattanakul et al., 2006) could have a saturating effect on cannabinoid receptors. Increasing receptor number could boost responsiveness to these increased endocannabinoids and thus bypass the need for exogenous agonists. Such a rationale has already been proposed for treatment of multiple sclerosis, in which CB 2 R on T cells was found to be highly activated in the experimental autoimmune encephalomyelitis model, presumably by increased levels of endocannabinoids (Maresz et al., 2007) . In other diseases, increasing cannabinoid receptor expression where it is lost could be an attractive therapeutic option. Loss of CB 1 R as a result of promoter methylation in colorectal cancer, as seen in human cell lines, could be rescued using a demethylating agent in the hopes of decreasing tumor proliferation (Wang et al., 2008) .
Alternatively, inhibition of cannabinoid receptor upregulation where it is harmful could be an attractive alternative to systemic antagonism. For example, CB 1 R antagonists have been proposed for treatment of liver fibrosis, which is marked by maladaptive up-regulation of CB 1 R (Teixeira-Clerc et al., 2006) . However, systemic use of the CB 1 R antagonist rimonabant for "prevention of cardiovascular events" (CRESCENDO trial) was terminated because of adverse neuropsychiatric effects (Topol et al., 2010) . A better alternative might be blockade of hepatic CB 1 R up-regulation; the retinoic acid system has already been implicated and could thus be a possible target (Mukhopadhyay et al., 2010) . Given that CB 1 R is normally expressed at very low levels in the liver (Teixeira-Clerc et al., 2006) and thus probably does not serve much of a role in normal liver physiology, inhibition of its up-regulation in the liver is likely to be safe.
IV. Cannabinoid Receptor Gene Structure
Our understanding of cannabinoid receptor gene structure, essential for studying its direct regulation, is relatively recent. Experimentally determined gene CB 1 R/CB 2 R REGULATION IN DISEASE structures and promoters of CB 1 R and CB 2 R are summarized here and in Fig. 1 .
A. Cannabinoid Receptor-1. In human, rat, and mouse, the CB 1 R coding region is contained within one exon and shows significant homology across species; however, there seems to be considerable variation in the length of 5Ј untranslated region (UTR). Zhang et al. (2004) identified three additional upstream exons in human CB 1 R using hippocampal RNA, giving a large (approximately 20 kb) 5Ј UTR characteristic of neuronally expressed genes. This 5ЈUTR can be alternatively spliced (CB 1 A-D) or transcribed at different sites (CB 1 A-D versus CB 1 E) to yield five possible transcripts with region-specific expression in the brain. The 3-kb sequence upstream from the exon1 transcription start site showed significant promoter activity in various CB 1 R-expressing neuroblastoma cell lines. 5Ј Flanking sequences of exon 3 yielded much lower promoter activity, consistent with the lower expression of transcript CB 1 E. The more active promoter upstream of exon1 was further investigated in T cells, which normally express low levels of CB 1 R (Börner et al., 2008) . It is noteworthy that positive and negative regulatory regions mediating basal expression of CB 1 R in resting T cells differed from findings in neuronal lines, suggesting cell-type specific CB 1 R promoter regulation. A functional signal transducer and activator of transcription-6 (STAT6) element located Ϫ2769 upstream from the exon1 start site was also found to mediate interleukin-4-inducible CB 1 R expression.
Mouse CB 1 R gene structure was studied by McCaw et al. (2004) using RNA from striatum. In contrast to human CB 1 R (namely the striatal transcripts isolated by Zhang et al., 2004) , the mouse gene contains a shorter 5ЈUTR, with only one additional exon located upstream of the coding exon. This exon contains multiple transcription start sites (with the major sites at the beginning of exon1); however, the promoter activities of these regions were not examined. Later studies identified direct interactions of retinoic acid receptor-␥ and steroidogenic factor-1 with the mouse CB 1 R promoter (Kim et al., 2008; Mukhopadhyay et al., 2010) ; however, these studies did not specify which putative promoter was examined.
The originally cloned CB 1 R from a rat cerebral cortex cDNA library (Matsuda et al., 1990 ) similarly consists of two exons; however, additional 5Ј exons have not been investigated. Homology between human and rodent 5ЈUTR has not been examined; in general, species comparison is more detailed for CB 2 R (see next section).
B. Cannabinoid Receptor-2. Like CB 1 R, the CB 2 R coding region is contained in a single exon and is flanked by upstream noncoding exons in human, mouse, and, debatably, rat. Human CB 2 R consists of three exons alternatively transcribed and spliced to yield isoforms CB 2 A and -B (Liu et al., 2009) . CB 2 B, the first cloned cDNA, is transcribed from a promoter proximal to exon2 and expressed most highly in immune cells and tissues. The more recently identified CB 2 A contains exon1 and exon3 and is generated from a promoter 5Ј proximal to exon1. In contrast to CB 2 B, CB 2 A is most highly expressed in testis and shows some expression in the brain.
Mouse CB 2 R similarly consists of three exons alternatively transcribed by two promoters (Onaivi et al., 2006; Liu et al., 2009) . In contrast to humans, however, both CB 2 A and CB 2 B are expressed predominantly in the spleen (Liu et al., 2009) . Rat CB 2 R gene structure seems more complex than that of human and mouse, although findings are conflicting. In Fig. 1 , we present findings by Liu et al. (2009) of CB 2 A and -B isoforms transcribed from promoters flanking exon 1 and 2, like human and mouse CB 2 R. Rat CB 2 A and -B also showed expression patterns similar to those of mouse. In contrast, Brown et al. (2002) identified three coding exons in rat CB 2 R using the same species and tissue (spleen).
Like CB 1 R, human and rodent CB 2 R differ in length of 5ЈUTR, with human CB 2 R again being considerably longer. Moreover, the CB 2 R 5ЈUTR showed little alignment between human-rodent (although rat-mouse 5ЈUTR aligned well, and there was significant homology in coding region across all species) (Liu et al., 2009) . The lack of The selection of studies was found through the Chromatin Enrichment Analysis database (ChEA) (http://amp.pharm.mssm.edu/lib/chea.jsp) (Lachmann et al., 2010 CB 1 R/CB 2 R REGULATION IN DISEASE significant homology in 5ЈUTR and different tissue distribution of CB 2 A and CB 2 B isoforms in humans versus rodents (with the 2A isoform appearing in the brain only in humans) suggests differential CB 2 R promoter regulation across species. Such differences in rodent and human CB 2 R isoform expression should also be kept in mind when interpreting results from animal models. For example, the human CB 2 A isoform could produce unwanted central nervous system effects because of its low expression in the brain; these effects would not be seen in mice (for review, see Campbell et al., 2001; Liu et al., 2009) .
The production of these alternative CB 1 R and CB 2 R transcripts differing in 5ЈUTR in disease is worth investigating. These transcripts have already been shown to have region-specific expression; they could also differ in mRNA stability, subcellular localization and translational efficacies (see references in Zhang et al., 2004) . The importance of the CB 1 R 5ЈUTR in disease is suggested by the presence of single-nucleotide polymorphisms in 5Ј UTR introns and exons (TAG haplotype) that are associated with lower mRNA levels and with substance abuse (Zhang et al., 2004) . It will also be important to identify the use of alternative promoters in disease when studying direct mechanisms of cannabinoid receptor regulation.
V. High-Throughput Studies of Transcription Factor Interactions with Cannabinoid Receptors 1 and 2
In addition to the directed studies of cannabinoid receptor promoter regulation (Table 2) , high-throughput chromatin immunoprecipitation (ChIP) studies using various cell lines have identified a number of transcription factors that interact with the CB 1 R and CB 2 R promoters. We used the Chromatin Enrichment Analysis database of such ChIP experiments (Lachmann et al., 2010) to compile a list of transcription factors that interact with CB 1 R and CB 2 R (Table 3) . Many of these transcription factors are implicated in DNA methylation and histone post-translational modifications, further supporting a role for epigenetic mechanisms in cannabinoid receptor regulation. These studies vary in their methods of defining target genes; often, regulatory regions are assigned based on a given distance (e.g., 50 kb) from a locus. Moreover, the binding of a transcription factor does not always mean that it has functional effects on transcription at a given locus (Chen et al., 2008) .
In addition to identifying transcription factors that interact with the cannabinoid receptor promoters through such ChIP studies, identifying transcription factors downstream of cannabinoid receptor signaling will be important for further studies of cannabinoid receptor autoregulation. Along these lines, Bromberg et al. (2008) identified 33 transcription factors activated in Neuro2A neuroblastoma cells after stimulation with cannabinoid receptor agonist using an array of transcription factor-binding site oligonucleotides. Taken together, transcription factors identified by these highthroughput studies can be starting points for further directed investigations of cannabinoid receptor regulation in disease.
VI. Conclusions and Future Directions
Alteration in cannabinoid receptor expression is appearing more and more to be a widespread response to disease. As investigation of the mechanisms underlying these changes continues, we will probably begin to see commonalities across diseases. Cytokines, growth factors, hormones, and other factors released in response to tissue injury and inflammation are thus rational starting points for further investigations of mechanism. Autoregulation of cannabinoid receptor expression will also likely be identified in other models. Findings of specific signaling pathways and transcription factors will hopefully be accompanied by identification of the epigenetic modifications ultimately underlying these expression changes.
Understanding these mechanisms of cannabinoid receptor regulation will hopefully expand our options for therapeutically targeting the endocannabinoid system. Selectively enhancing receptor expression could allow for lower doses of systemic agonists or eliminate the need for them altogether; selectively inhibiting expression could likewise avoid systemic antagonism. These improved endocannabinoid system-based therapies could have a lot to offer medicine.
